

# VP Monet Blue Diluent

Diluent  
901-VPD901-052623

**BIOCARE**  
M E D I C A L

Available Product Formats	
Catalog Number	Volume
VPD901L	100 mL

## Intended Use:

For *in vitro* Diagnostic Use

The VP Monet Blue Diluent is intended for laboratory professional use to dilute antibodies to an optimal concentration for use in performing either manual or automated Immunohistochemistry (IHC) staining protocols on formalin-fixed, paraffin embedded (FFPE) tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies and proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

## Summary and Explanation:

The VP Monet Blue Diluent is designed as a Tris-based diluent for titrating primary antibodies used in immunohistochemistry. An aqueous environment greatly influences antibody conformations. Antibody diluents used to dilute antibodies for use in IHC staining protocols are intended to stabilize the antibody and maintain the binding properties of the antibody with the associated target antigen. Charge, hydrophobicity, and other physiological/chemical properties can affect antibody-diluent combinations. Binding of antigens to antibodies is pH dependent and highly controlled by ionic interactions. Antibody diluents are typically either Tris or Phosphate buffered solutions which may contain additives, such as salts and azides to reduce non-specific interactions which can alter antibody-antigen binding.

VP Monet Blue Diluent is specifically formulated to enhance certain types of primary antibodies on Ventana immunostainers. VP Monet Blue Diluent uses Biocare's Assure Technology, which is a colored-coded product (VP Monet Blue) with pH indicator. If the pale blue diluent changes color to green or yellow, it indicates that a pH change has occurred, and that optimum staining may be hindered.

## Principle of Procedure:

This reagent when used in conjunction with a primary antibody when applied to pretreated formalin-fixed, paraffin embedded tissue sections enhance primary antibody staining.

## Materials and Methods:

### Reagents Provided:

Kit Catalog No.	Component Description	Quantity x Volume
PD901H	VP Monet Blue Diluent	1 x 25 mL
PD901L	VP Monet Blue Diluent	1 x 100 mL
PD901M	VP Monet Blue Diluent	1 x 500 mL

## Reconstitution, Mixing, Dilution, Titration:

The VP Monet Blue Diluent is optimized and ready to use with Biocare IHC antibodies. No reconstitution, mixing, dilution, or titration is required.

## Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

**Supplied As:** Buffered saline solution, pH 8.2 ± 0.1 at room temperature (RT), containing a protein carrier and <0.1% sodium azide preservative. See Safety Data Sheet for additional details.

## Materials and Reagents Needed But Not Provided:

Primary Antibody  
Microscope slides, positively charged  
Positive and negative tissue controls  
Desert Chamber (or similar Drying oven)  
Xylene or xylene substitute  
Ethanol or reagent alcohol  
Decloaking Chamber (Pressure cooker)  
Deionized or distilled water  
Wash buffer  
Pretreatment reagents  
Peroxidase block (optional)  
Protein block (optional)  
Detection probe and polymer  
Negative control reagents  
Chromogens  
Hematoxylin (counterstain)  
Bluing reagent  
Mounting medium  
Coverglass  
Light Microscope (40-400X magnification)

Configurations of the antibody product are available for use on the instruments indicated in the table above.

## Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the vial label, when stored under these conditions. Do not use after expiration date. Storage under any condition other than those specified must be verified. Diluted reagents should be used promptly; store any remaining reagent at 2°C to 8°C. The stability of user diluted reagent has not been established by Biocare. Store away from light. Protect product from prolonged exposure to light.

Positive and negative controls should be run simultaneously with all patient specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the reagent is suspected, contact Biocare's Technical Support at 1-800-542-2002 or via the technical support information provided on biocare.net.

## Specimen Preparation:

Tissues fixed in formalin are suitable for use prior to paraffin embedding. Osseous tissues should be decalcified prior to tissue processing to facilitate tissue cutting and prevent damage to microtome blades.<sup>1,2</sup>


Properly fixed and embedded tissues expressing the specified antigen target should be stored in a cool place. The Clinical Laboratory Improvement Act (CLIA) of 1988 requires in 42 CFR §493.1259(b) that "The laboratory must retain stained slides at least ten years from the date of examination and retain specimen blocks at least two years from the date of examination."<sup>3</sup>

## Treatment of Tissues Prior to Staining:

Perform Heat Induced Epitope Retrieval (HIER) per recommended protocol below. The routine use of HIER prior to IHC has been shown to minimize inconsistency and standardize staining.<sup>4,5</sup>

## Warning and Precautions:

- Kit reagent(s) contain less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN<sub>3</sub>) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976)<sup>6</sup>
- Handle materials of human or animal origin as potentially biohazardous and dispose such materials with proper precautions. In the event of

 Biocare Medical  
60 Berry Drive  
Pacheco, CA 94553  
USA



TP v1 (07/05/2022)

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080

 EMERGO EUROPE

Westervoortsedijk 60

6827 AT Arnhem

The Netherlands

# VP Monet Blue Diluent

Diluent  
901-VPD901-052623

**BIOCARE**  
M E D I C A L

exposure, follow the health directives of the responsible authorities where used.<sup>7,8</sup>

3. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water.<sup>9</sup>

4. Microbial contamination of reagents may result in an increase in nonspecific staining.

5. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

6. Do not use reagent after the expiration date printed on the vial.

7. The antibody diluent is optimized and ready to use with Biocare antibodies. Refer to the primary antibody and other ancillary reagent instructions for use for recommended protocols and conditions for use.

8. Follow local and/or state authority requirements for method of disposal.

9. The SDS is available upon request and is located at <http://biocare.net>.

10. Report any serious incidents related to this device by contacting the local Biocare representative and the applicable competent authority of the Member State or country where the user is located.

## **Instructions for Use:**

VP Monet Blue Diluent was developed for use with primary antibodies. Please refer to the respective primary antibody datasheet for dilution information.

When using an automated staining instrument, consult the specific instrument operator manual and instructions for use for operating parameters.

**Technical Note:** Store away from light. Protect product from prolonged exposure to light.

## **Quality Control:**

Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA ([www.clsi.org](http://www.clsi.org)). 2011<sup>8</sup>

## **Positive Tissue Control:**

External positive control materials should be fresh specimens fixed, processed, and embedded as soon as possible in the same manner as the patient sample(s). Positive tissue controls are indicative of correctly prepared tissues and proper staining techniques. One positive external tissue control for each set of test conditions should be included in each staining run.

The tissues used for the external positive control materials should be selected from patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed so to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the IHC methodology. Commercially available tissue control slides or specimens processed differently from the patient sample(s) validate reagent performance only and do not verify tissue preparation.

Known positive tissue controls should only be utilized for monitoring the correct performance of processed tissues and test reagents, rather than as an aid in formulating a specific diagnosis of patient samples. If the positive tissue controls fail to demonstrate positive staining, results with the test specimens should be considered invalid.

## **Negative Tissue Control:**

Use a negative tissue control fixed, processed, and embedded in a manner identical to the patient sample(s) with each staining run to verify the specificity of the IHC primary antibody for demonstration of the target antigen, and to provide an indication of specific background staining (false positive staining). Also, the variety of different cell types present in most

tissue sections can be used by the laboratorian as internal negative control sites to verify the IHC's performance specifications. The types and sources of specimens that may be used for negative tissue controls are listed in the Performance Characteristics section.

If specific staining (false positive staining) occurs in the negative tissue control, results with the patient specimens should be considered invalid.

## **Nonspecific Negative Reagent Control:**

Use a nonspecific negative reagent control in place of the primary antibody with a section of each patient specimen to evaluate nonspecific staining and allow better interpretation of specific staining at the antigen site. Ideally, a negative reagent control contains an antibody produced and prepared (i.e. diluted to same concentration using same diluent) for use in the same way as the primary antibody but exhibits no specific reactivity with human tissues in the same matrix/solution as the Biocare antibody. Diluent alone may be used as a less desirable alternative to the previously described negative reagent controls. The incubation period for the negative reagent control should correspond to that of the primary antibody.

When panels of several antibodies are used on serial sections, the negatively staining areas of one slide may serve as a negative/nonspecific binding background control for other antibodies. To differentiate endogenous enzyme activity or nonspecific binding of enzymes from specific immunoreactivity, additional patient tissues may be stained exclusively with substrate-chromogen or enzyme complexes (PAP, avidin-biotin, streptavidin) and substrate-chromogen, respectively.

## **Assay Verification:**

Prior to initial use of an antibody or staining system in a diagnostic procedure, the user should verify the antibody's specificity by testing it on a series of in-house tissues with known immunohistochemical performance characteristics representing known positive and negative tissues. Refer to the quality control procedures previously outlined in this section of the product insert and to the quality control recommendations of the CAP Certification Program<sup>11</sup> for Immunohistochemistry and/or the NCCLS IHC guideline<sup>12</sup>. These quality control procedures should be repeated for each new antibody lot, or whenever there is a change in assay parameters. Tissues listed in the Performance Characteristics section are suitable for assay verification.

## **Troubleshooting:**

Follow the antibody specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

## **Interpretation of Staining:**

A primary antibody works in conjunction with ancillary reagents to produce a colored reaction at the antigen sites localized by the primary antibody. Diluent ancillary reagents assist with providing a pH buffered environment to facilitate primary antibody binding in the antibody-antigen specific staining reaction. Prior to interpretation of patient results, the staining of controls must be evaluated by a qualified pathologist. Negative controls are evaluated and compared to stained slides to ensure any staining observed is not a result of nonspecific interactions.

## **Positive Tissue Control:**

The positive tissue control stained with indicated antibody should be examined first to ascertain that all reagents are functioning properly. The appropriate staining of target cells (as indicated above) is indicative of positive reactivity. If the positive tissue controls fail to demonstrate positive staining, any results with the test specimens should be considered invalid.

The color of the reaction product may vary depending on substrate chromogens used. Refer to substrate package inserts for expected color reactions. Further, metachromasia may be observed in variations of the method of staining.<sup>11</sup>



60 Berry Drive  
Pacheco, CA 94553  
USA



TP v1 (07/05/2022)

Tel: 800-799-9499 | [www.biocare.net](http://www.biocare.net) | Fax: 925-603-8080



Westervoortsedijk 60  
6827 AT Arnhem  
The Netherlands

# VP Monet Blue Diluent

Diluent  
901-VPD901-052623

**BIOCARE**  
M E D I C A L

When a counterstain is used, depending on the incubation length and potency of the counterstain used, counterstaining will result in a coloration of the cell nuclei. Excessive or incomplete counterstaining may compromise proper interpretation of results. Refer to protocol(s) for recommended counterstain.

## Negative Tissue Control:

The negative tissue control should be examined after the positive tissue control to verify the specificity of the labeling of the target antigen by the primary antibody. The absence of specific staining in the negative tissue control confirms the lack of antibody cross reactivity to cells/cellular components. If specific staining (false positive staining) occurs in the negative external tissue control, results with the patient specimen should be considered invalid.

Nonspecific staining, if present, usually has a diffuse appearance. Sporadic staining of connective tissue may also be observed in sections from excessively formalin-fixed tissues. Use intact cells for interpretation of staining results. Necrotic or degenerated cells often stain nonspecifically.

## Patient Tissue:

Examine patient specimens stained with indicated antibody last. Positive staining intensity should be assessed within the context of any nonspecific background staining of the negative reagent control. As with any immunohistochemical test, a negative result means that the antigen was not detected, not that the antigen was absent in the cells/tissue assayed. If necessary, use a panel of antibodies to identify false-negative reactions.

Refer to Summary and Explanation, Limitations, and Performance Characteristics for specific information regarding indicated antibody immunoreactivity.

## **Limitations:**

### General Limitations:

1. For *in vitro* diagnostic Use
2. This product is for professional use only: Immunohistochemistry is a multistep diagnostic process that consists of specialized training in the selection of the appropriate reagents; tissue selection, fixation, and processing; preparation of the IHC slide; and interpretation of the staining results.
3. Tissue staining is dependent on the handling and processing of the tissue prior to staining. Improper fixation, freezing, thawing, washing, drying, heating, sectioning or contamination with other tissues or fluids may produce artifacts, antibody trapping, or false negative results. Inconsistent results may be due to variations in fixation and embedding methods, or to inherent irregularities within the tissue.<sup>12</sup>
4. Excessive or incomplete counterstaining may compromise proper interpretation of results.
5. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology, and other histopathological criteria. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests. It is the responsibility of a qualified pathologist who is familiar with the proper use of IHC antibodies, reagents, and methods to interpret all the steps used to prepare and interpret the final IHC preparation.
6. The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

7. This product is not intended for use in flow cytometry. Performance characteristics have not been determined for flow cytometry.
8. Tissues from persons infected with hepatitis B virus and containing hepatitis B surface antigen (HBsAg) may exhibit nonspecific staining with horseradish peroxidase.<sup>13</sup>
9. Reagents may demonstrate unexpected reactions in previously untested tissues. The possibility of unexpected reactions even in tested tissue groups cannot be completely eliminated due to biological variability of antigen expression in neoplasms, or other pathological tissues.<sup>14</sup> Contact Biocare's Technical Support at 1-800-542-2002, or via the technical support information provided on biocare.net, with documented unexpected reaction(s).
10. Normal/nonimmune sera from the same animal source as secondary antisera used in blocking steps may cause false-negative or false-positive results due to autoantibodies or natural antibodies.
11. False-positive results may be seen due to non-immunological binding of proteins or substrate reaction products. They may also be caused by pseudo peroxidase activity (erythrocytes), endogenous peroxidase activity (cytochrome C), or endogenous biotin (e.g., liver, breast, brain, kidney) depending on the type of immunostain used.<sup>12</sup>

## Product Specific Limitations:

*Product is sensitive to light. Store away from light and protect product from prolonged exposure.*

## **Performance Characteristics:**

Staining was performed using protocols provided in the antibody specific instructions for use or as specified. Sensitivity and specificity of staining was evaluated across a range of normal and neoplastic tissue types evaluated during development of primary antibodies.

## Reproducibility:

The reproducibility of Biocare's diluent reagents is verified through a measurement of intermediate precision in which various reagent lots were tested over an extended period of time using various operators, analysts, reagent lots, tissue samples, and equipment. The staining obtained for each diluent reagent evaluated was consistent and performed as expected.

## **Troubleshooting:**

1. No staining of any slides – Check to determine appropriate positive control tissue, antibody, and detection products have been used. Check for incomplete or improper wax removal or pretreatment.
2. Weak staining of all slides – Check to determine appropriate positive control tissue, antibody, and detection products have been used.
3. Excessive background of all slides – There may be high levels of endogenous biotin (if using biotin-based detection products), endogenous HRP activity converting chromogen to colored end product (use peroxidase block), or excess non-specific protein interaction (use a protein block, such as serum- or casein-based blocking solution).
4. Tissue sections wash off slides during incubation – Check slides to ensure they are positively charged.
5. Specific staining too dark – Check protocol to determine if proper antibody titer was applied to slide, as well as proper incubation times for all reagents. Additionally, ensure the protocol has enough washing steps to remove excess reagents after incubation steps are completed.

# VP Monet Blue Diluent

Diluent  
901-VPD901-052623

**BIOCARE**  
M E D I C A L

## References:

1. Kiernan JA. *Histological and Histochemical Methods: Theory and Practice*. New York: Pergamon Press 1981.
2. Sheehan DC and Hrapchak BB. *Theory and Practice of Histotechnology*. St. Louis: C.V. Mosby Co. 1980.
3. Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992.
4. Shi S-R, Cote RJ, Taylor CR. *J Histotechnol*. 1999 Sep;22(3):177-92.
5. Taylor CR, et al. *Biotech Histochem*. 1996 Jan;71(5):263-70.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts.
7. Occupational Safety and Health Standards: Occupational exposure to hazardous chemicals in laboratories. (29 CFR Part 1910.1450). Fed. Register.
8. Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.
9. Clinical and Laboratory Standards Institute (CLSI). *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition* CLSI document M29-A4 Wayne, PA 2014.
10. CLSI *Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2)* CLSI Wayne, PA USA ([www.clsi.org](http://www.clsi.org)). 2011
11. College of American Pathologists (CAP) Certification Program for Immunohistochemistry. Northfield IL. [Http://www.cap.org](http://www.cap.org) (800) 323-4040.
12. O'Leary TJ, Edmonds P, Floyd AD, Mesa-Tejada R, Robinowitz M, Takes PA, Taylor CR. *Quality assurance for immunocytochemistry; Proposed guideline. MM4-P. National Committee for Clinical Laboratory Standards (NCCLS). Wayne, PA. 1997;1-46.*
13. Koretzik K, Lemain ET, Brandt I, and Moller P. *Metachromasia of 3-amino-9-ethylcarbazole (AEC) and its prevention in Immunoperoxidase techniques. Histochemistry 1987; 86:471-478.*
14. Nadji M, Morales AR. *Immunoperoxidase, part I: the techniques and its pitfalls. Lab Med 1983; 14:767.*
15. Omata M, Liew CT, Ashcavai M, Peters RL. *Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen: a possible source of error in immunohistochemistry. AmJ Clin Path 1980; 73:626.*
16. Herman GE and Elfont EA. *The taming of immunohistochemistry: the new era of quality control. Biotech & Histochem 1991; 66:194.*

Ultraline products are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Ventana Medical Systems, Inc or Roche. Biocare, Ventana and Roche are not affiliated, associated, or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.